DALLAS, Jan. 14, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring MDRNA Inc. (Nasdaq:MRNA). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
It is available at: http://www.beaconequity.com/i/MRNA
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
MDRNA Inc. (MRNA) is a biotechnology company focused on the discovery, development and commercialization of pharmaceuticals based on RNA interference (RNAi). The Company's infrastructure provides for pre-clinical scale manufacturing of both siRNAs and delivery materials, the comprehensive analysis and optimization of these compounds both individually and as drug candidates, and the filing of Investigational New Drug Applications. The Company develops RNAi-based product candidates for the treatment of cancer, metabolic disorders, inflammation and viral infections.
Message Board Search for MRNA: http://www.boardcentral.com/boards/MRNA
In the report, the analyst notes:
"Net loss for the third quarter of 2009 was approximately $7.0 million or $0.17 per share, compared to a net loss of approximately $16.1 million or $0.52 per share for the same period of 2008. The net loss for the nine months ended September 30, 2009, was approximately $7.3 million or $0.20 per share, compared to approximately $46.9 million or $1.62 per share for the prior year same nine-month period.
"MRNA recently reported in vivo data for bladder and liver cancer demonstrating further advancement of the Company's oncology programs. The Company reported a reduction in tumor growth in both liver and bladder cancers by targeting genes key to tumor progression, via both systemic and local delivery with the Company's proprietary UsiRNAs delivered by its novel DiLA2 platform. In addition, MRNA disclosed the establishment of an early collaborative effort with a major international pharmaceutical company, its second such effort."
To read the entire report visit: http://www.beaconequity.com/i/MRNA
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.